Petlife Pharmaceuticals Inc
Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concen… Read more
Petlife Pharmaceuticals Inc (PTLF) - Total Assets
Latest total assets as of February 2018: $7.86K USD
Based on the latest financial reports, Petlife Pharmaceuticals Inc (PTLF) holds total assets worth $7.86K USD as of February 2018.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Petlife Pharmaceuticals Inc - Total Assets Trend (2006–2017)
This chart illustrates how Petlife Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Petlife Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (August 2017)
Petlife Pharmaceuticals Inc's total assets of $7.86K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2017)
This chart illustrates how Petlife Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Petlife Pharmaceuticals Inc's current assets represent 100.0% of total assets in 2017, unchanged from 100.0% in 2006.
- Cash Position: Cash and equivalents constituted 98.6% of total assets in 2017, up from 81.4% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Petlife Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Petlife Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Petlife Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Petlife Pharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Petlife Pharmaceuticals Inc is currently not profitable relative to its asset base.
Petlife Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.19 | 0.01 |
| Quick Ratio | 0.00 | 0.19 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.97 Million | $ -912.42K | $ -1.06 Million |
Petlife Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Petlife Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 4593.2% |
| Total Assets | $55.00K |
| Market Capitalization | $7.23K USD |
Valuation Analysis
Below Book Valuation: The market values Petlife Pharmaceuticals Inc's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Petlife Pharmaceuticals Inc's assets grew by 4593.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Petlife Pharmaceuticals Inc (2006–2017)
The table below shows the annual total assets of Petlife Pharmaceuticals Inc from 2006 to 2017.
| Year | Total Assets | Change |
|---|---|---|
| 2017-08-31 | $55.00K | +4593.17% |
| 2016-08-31 | $1.17K | -78.30% |
| 2015-08-31 | $5.40K | -69.03% |
| 2014-08-31 | $17.43K | -97.75% |
| 2012-08-31 | $776.43K | -2.37% |
| 2011-08-31 | $795.30K | +183149.54% |
| 2010-08-31 | $434.00 | -91.32% |
| 2009-08-31 | $5.00K | +14.71% |
| 2008-08-31 | $4.36K | -90.88% |
| 2007-08-31 | $47.79K | +68.79% |
| 2006-08-31 | $28.31K | -- |